Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
71
PODD Quote, Financials, Valuation and Earnings
Last price:
$315.86
Seasonality move
:
4.29%
Day range:
$305.05 - $317.34
52-week range:
$230.05 - $354.88
Dividend yield:
0%
P/E ratio:
91.66x
P/S ratio:
9.07x
P/B ratio:
16.06x
Volume:
757.1K
Avg. volume:
712.6K
1-year change:
17.35%
Market cap:
$22.2B
Revenue:
$2.1B
EPS (TTM):
$3.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$679M | $1.15 | 28.59% | 5.39% | $378.21 |
|
BAX
Baxter International, Inc.
|
$2.9B | $0.60 | 2.57% | 118.69% | $23.80 |
|
BSX
Boston Scientific Corp.
|
$5B | $0.71 | 15.72% | 105.56% | $126.48 |
|
PAHC
Phibro Animal Health Corp.
|
$345.4M | $0.60 | 15% | 756.68% | $43.00 |
|
RMD
ResMed, Inc.
|
$1.3B | $2.50 | 8.96% | 15.63% | $293.47 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$235.8M | -$0.34 | -2.05% | -4.07% | $22.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$315.92 | $378.21 | $22.2B | 91.66x | $0.00 | 0% | 9.07x |
|
BAX
Baxter International, Inc.
|
$18.48 | $23.80 | $9.5B | 167.20x | $0.01 | 2.81% | 0.86x |
|
BSX
Boston Scientific Corp.
|
$97.72 | $126.48 | $144.9B | 52.27x | $0.00 | 0% | 7.54x |
|
PAHC
Phibro Animal Health Corp.
|
$40.77 | $43.00 | $1.7B | 24.51x | $0.12 | 1.18% | 1.19x |
|
RMD
ResMed, Inc.
|
$251.51 | $293.47 | $36.7B | 25.74x | $0.60 | 0.9% | 7.04x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$20.71 | $22.52 | $1.4B | -- | $0.00 | 0% | 1.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PODD
Insulet Corp.
|
42.7% | 1.380 | 4.75% | 1.89x |
|
BAX
Baxter International, Inc.
|
57.29% | 0.027 | 83.18% | 0.96x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.345 | 8.31% | 0.81x |
|
PAHC
Phibro Animal Health Corp.
|
71.58% | 2.736 | 47.87% | 1.12x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.243 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PODD
Insulet Corp.
|
$513.5M | $117.7M | 9.14% | 18.92% | 16.66% | $94.6M |
|
BAX
Baxter International, Inc.
|
$938M | $194M | -1.9% | -4.83% | 6.84% | $126M |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
PAHC
Phibro Animal Health Corp.
|
$119.3M | $47.9M | 6.8% | 24.77% | 13.16% | -$4.5M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Insulet Corp. vs. Competitors
-
Which has Higher Returns PODD or BAX?
Baxter International, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of -1.8%. Insulet Corp.'s return on equity of 18.92% beat Baxter International, Inc.'s return on equity of -4.83%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B BAXBaxter International, Inc.33.09% $0.02 $16.9B -
What do Analysts Say About PODD or BAX?
Insulet Corp. has a consensus price target of $378.21, signalling upside risk potential of 19.72%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.80 which suggests that it could grow by 28.79%. Given that Baxter International, Inc. has higher upside potential than Insulet Corp., analysts believe Baxter International, Inc. is more attractive than Insulet Corp..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.18 2 0 BAXBaxter International, Inc.2 13 1 -
Is PODD or BAX More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.771%.
-
Which is a Better Dividend Stock PODD or BAX?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.81% to investors and pays a quarterly dividend of $0.01 per share. Insulet Corp. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or BAX?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. Insulet Corp.'s net income of $87.6M is higher than Baxter International, Inc.'s net income of -$51M. Notably, Insulet Corp.'s price-to-earnings ratio is 91.66x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 9.07x versus 0.86x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.9.07x 91.66x $706.3M $87.6M BAXBaxter International, Inc.0.86x 167.20x $2.8B -$51M
-
Which has Higher Returns PODD or BSX?
Boston Scientific Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 14.91%. Insulet Corp.'s return on equity of 18.92% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About PODD or BSX?
Insulet Corp. has a consensus price target of $378.21, signalling upside risk potential of 19.72%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 29.43%. Given that Boston Scientific Corp. has higher upside potential than Insulet Corp., analysts believe Boston Scientific Corp. is more attractive than Insulet Corp..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.18 2 0 BSXBoston Scientific Corp.25 2 0 -
Is PODD or BSX More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.
-
Which is a Better Dividend Stock PODD or BSX?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or BSX?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Insulet Corp.'s net income of $87.6M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Insulet Corp.'s price-to-earnings ratio is 91.66x while Boston Scientific Corp.'s PE ratio is 52.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 9.07x versus 7.54x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.9.07x 91.66x $706.3M $87.6M BSXBoston Scientific Corp.7.54x 52.27x $5.1B $755M
-
Which has Higher Returns PODD or PAHC?
Phibro Animal Health Corp. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 7.29%. Insulet Corp.'s return on equity of 18.92% beat Phibro Animal Health Corp.'s return on equity of 24.77%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B PAHCPhibro Animal Health Corp.32.8% $0.65 $1.1B -
What do Analysts Say About PODD or PAHC?
Insulet Corp. has a consensus price target of $378.21, signalling upside risk potential of 19.72%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Insulet Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Insulet Corp. is more attractive than Phibro Animal Health Corp..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.18 2 0 PAHCPhibro Animal Health Corp.0 2 0 -
Is PODD or PAHC More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.
-
Which is a Better Dividend Stock PODD or PAHC?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Insulet Corp. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PODD or PAHC?
Insulet Corp. quarterly revenues are $706.3M, which are larger than Phibro Animal Health Corp. quarterly revenues of $363.9M. Insulet Corp.'s net income of $87.6M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Insulet Corp.'s price-to-earnings ratio is 91.66x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 9.07x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.9.07x 91.66x $706.3M $87.6M PAHCPhibro Animal Health Corp.1.19x 24.51x $363.9M $26.5M
-
Which has Higher Returns PODD or RMD?
ResMed, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of 26.1%. Insulet Corp.'s return on equity of 18.92% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About PODD or RMD?
Insulet Corp. has a consensus price target of $378.21, signalling upside risk potential of 19.72%. On the other hand ResMed, Inc. has an analysts' consensus of $293.47 which suggests that it could grow by 16.68%. Given that Insulet Corp. has higher upside potential than ResMed, Inc., analysts believe Insulet Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.18 2 0 RMDResMed, Inc.9 6 1 -
Is PODD or RMD More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock PODD or RMD?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Insulet Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PODD or RMD?
Insulet Corp. quarterly revenues are $706.3M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Insulet Corp.'s net income of $87.6M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Insulet Corp.'s price-to-earnings ratio is 91.66x while ResMed, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 9.07x versus 7.04x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.9.07x 91.66x $706.3M $87.6M RMDResMed, Inc.7.04x 25.74x $1.3B $348.5M
-
Which has Higher Returns PODD or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 12.4% compared to Insulet Corp.'s net margin of -8.49%. Insulet Corp.'s return on equity of 18.92% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital PODDInsulet Corp.72.7% $1.24 $2.4B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About PODD or TNDM?
Insulet Corp. has a consensus price target of $378.21, signalling upside risk potential of 19.72%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $22.52 which suggests that it could grow by 8.76%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PODDInsulet Corp.18 2 0 TNDMTandem Diabetes Care, Inc.6 14 0 -
Is PODD or TNDM More Risky?
Insulet Corp. has a beta of 1.374, which suggesting that the stock is 37.428% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.
-
Which is a Better Dividend Stock PODD or TNDM?
Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PODD or TNDM?
Insulet Corp. quarterly revenues are $706.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Insulet Corp.'s net income of $87.6M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Insulet Corp.'s price-to-earnings ratio is 91.66x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 9.07x versus 1.37x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PODDInsulet Corp.9.07x 91.66x $706.3M $87.6M TNDMTandem Diabetes Care, Inc.1.37x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
